Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents

被引：0
|
作者：
Hideaki Miyake
Ryo Sato
Kyohei Watanabe
Yuto Matsushita
Hiromitsu Watanabe
Daisuke Motoyama
Toshiki Ito
Takayuki Sugiyama
Atsushi Otsuka
机构：
[1] Hamamatsu University School of Medicine,Department of Urology
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Metastatic castration-resistant prostate cancer; Cabazitaxel; Third-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1745 / 1751
页数：6
相关论文
共 50 条
  • [41] An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
    Carles, Joan
    Pichler, Angelika
    Korunkova, Hana
    Tomova, Antoaneta
    Ghosn, Marwan
    El Karak, Fadi
    Makdessi, Joseph
    Koroleva, Irina
    Barnes, Gisoo
    Bury, Denise
    Ozatilgan, Ayse
    Hitier, Simon
    Katolicka, Jana
    BJU INTERNATIONAL, 2019, 123 (03) : 456 - 464
  • [42] Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer
    Yamamoto, Yutaka
    Nishimoto, Mituhisa
    Akashi, Yasunori
    Kiba, Keisuke
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Hirayama, Akihide
    Uemura, Hirotsugu
    Fujita, Kazutoshi
    ANTICANCER RESEARCH, 2024, 44 (07) : 3155 - 3161
  • [43] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05) : 558 - 567
  • [44] Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Beuzeboc, Philippe
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Greilsamer, Charlotte
    Hon, Thierry Nguyen Tan
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Ratta, Raffaele
    Flechon, Aude
    Cheneau, Caroline
    Maillard, Aline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    EUROPEAN UROLOGY, 2022, 81 (03) : 234 - 240
  • [45] Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France
    Pouessel, Damien
    Oudard, Stephane
    Gravis, Gwenaelle
    Priou, Frank
    Shen, Liji
    Culine, Stephane
    BULLETIN DU CANCER, 2012, 99 (7-8) : 731 - 741
  • [46] Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
    Koinis, Filippos
    Zafeiriou, Zafeiris
    Messaritakis, Ippokratis
    Katsaounis, Panagiotis
    Koumarianou, Anna
    Kontopodis, Emmanouil
    Chantzara, Evangelia
    Aidarinis, Chrissovalantis
    Lazarou, Alexandros
    Christodoulopoulos, George
    Emmanouilides, Christos
    Hatzidaki, Dora
    Kallergi, Galatea
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CANCERS, 2023, 15 (18)
  • [47] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Hideaki Miyake
    Takayuki Sugiyama
    Ryota Aki
    Yuto Matsushita
    Keita Tamura
    Daisuke Motoyama
    Toshiki Ito
    Atsushi Otsuka
    Medical Oncology, 2017, 34
  • [48] Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
    Lorente, David
    Llacer, Casilda
    Lozano, Rebeca
    de Velasco, Guillermo
    Romero-Laorden, Nuria
    Rodrigo, Miguel
    Sanchez-Iglesias, Angel
    di Capua, Carlos
    Castro, Elena
    Ferrer, Carlos
    Sanchez-Hernandez, Alfredo
    Olmos, David
    EUROPEAN UROLOGY, 2021, 80 (05) : 641 - 649
  • [49] Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study
    Shiota, Masaki
    Nakamura, Motonobu
    Yokomizo, Akira
    Tomoda, Toshihisa
    Sakamoto, Naotaka
    Seki, Narihito
    Hasegawa, Shuji
    Yunoki, Takakazu
    Harano, Masahiko
    Kuroiwa, Kentaro
    Eto, Masatoshi
    ANTI-CANCER DRUGS, 2020, 31 (03) : 298 - 303
  • [50] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Sugiyama, Takayuki
    Aki, Ryota
    Matsushita, Yuto
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Otsuka, Atsushi
    MEDICAL ONCOLOGY, 2017, 34 (08)
12345